Table 2.
SARS-CoV-2 serological status in patients with SLE and SARS-CoV-2 RT-PCR positivity
| SARS-CoV-2 antibody-positive patients (n=24) | SARS-CoV-2 antibody-negative patients (n=5) | ||
|---|---|---|---|
| Sex | |||
| Female | 23 (96%) | 4 (80%) | |
| Male | 1 (4%) | 1 (20%) | |
| Age, years | 44·2 (15·7) | 42·6 (14·3) | |
| Ethnicity | |||
| Hispanic | 6 (25%) | 3 (60%) | |
| Not Hispanic | 18 (75%) | 2 (40%) | |
| Race | |||
| White | 10 (42%) | 2 (40%) | |
| Black | 10 (42%) | 2 (40%) | |
| Asian | 2 (8%) | 0 (0%) | |
| Other | 2 (8%) | 1 (20%) | |
| Medications | |||
| Immunosuppressants* | 15 (63%) | 3 (60%) | |
| Hydroxychloroquine | 21 (88%) | 5 (100%) | |
| Glucocorticoid | 7 (29%) | 3 (60%) | |
| Dose of prednisone equivalent, mg | 5 (4–5) | 5 (5–5) | |
| Time from SARS-CoV-2 RT-PCR to first antibody test, weeks | 12·4 (8·9) | 13·8 (8·3) | |
Data are n (%) for categorical variables and mean (SD) or median (IQR) for continuous variables. SLE=systemic lupus erythematosus.
*
Immunosuppressants include azathioprine, mycophenolate mofetil, methotrexate, belimumab, tacrolimus, cyclophosphamide, obinutuzumab, and rituximab.